Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3months: post hoc analyses from the tREACH study
Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3months: post hoc analyses from the tREACH study
复制标题
DOI：
10.1136/annrheumdis-2012-202152
复制
发表时间：
2013-10-01
影响因子：
27.4
通讯作者：
Hazes, J. M.
中科院分区：
文献类型：
--
作者：
de Jong, Pascal Hendrik Pieter;Quax, Rogier A.;Hazes, J. M.
目的探讨2周时的糖皮质激素反应（GC）是否可以预测3个月时的活动性疾病（疾病活动评分（DAS） bbb2.4）。方法本研究采用了鹿特丹早期关节炎队列研究（tREACH）的治疗数据，该研究是一项正在进行的临床试验，评估早期类风湿关节炎的不同诱导疗法。我们选择进展为持续性关节炎的概率较高的患者（根据Visser预测模型bbb70 %）。所有在高概率阶层的患者，在随机分组后2周基线DAS bbb2.2和DAS评估，被纳入（n=120）。除了2周时的GC反应外，我们还研究了在治疗3个月的抗风湿药物（DMARD）治疗后，哪些其他因素与活动性疾病（DAS>2.4）相关。所有p0.25的变量在我们的logistic回归模型中进行反向选择评估。排除变量，直到所有剩余变量具有显著相关性(p
ObjectiveTo investigate if a glucocorticoid (GC) response at 2weeks, defined by EULAR response criteria, can predict active disease (Disease Activity Score (DAS)>2.4) at 3months.MethodsFor this study, data of the Treatment in the Rotterdam Early Arthritis Cohort study (tREACH), an ongoing clinical trial that evaluates different induction therapies in early rheumatoid arthritis, were used. We selected patients who had a high probability of progressing to persistent arthritis (>70% based on the prediction model of Visser). All patients within the high-probability stratum, who had a baseline DAS>2.2 and a DAS assessment at 2weeks after randomisation, were included (n=120). Besides GC response at 2weeks, we investigated which other factors were associated with active disease (DAS>2.4) after 3months of disease-modifying antirheumatic drug (DMARD) treatment. All variables with a p0.25 were assessed in our logistic regression model with backward selection. Variables were eliminated until all remaining variables had a significant association (p